@FierceMedDev: Researchers develop the first blood test to diagnose adult depression. Story | Follow @FierceMedDev
@MichaelGFierce: Vaxxas' nanopatch garners WHO support in search of polio vax application. FierceDrugDelivery story | Follow @MichaelGFierce
@VarunSaxena2: Drug delivery specialist Genisphere receives an additional $2M in funding. FierceDrugDelivery article | Follow @VarunSaxena2
@EmilyWFierce: Mainstay Medical CEO reveals company's path to market for its neuromodulation implant. More | Follow @EmilyWFierce
> Boston Scientific received a CE mark for its Vercise deep brain simulation treatment device to patients with tremors. Release
> Using an electronic nose, researchers at the University of Leicester, have figured out a way to sniff out traces of infectious diseases in patients feces. News
> The cost-effective manufacturing practice of 3-D printing ultra-thin layers of material is coming soon from Northeastern University researchers. Story
Biotech News
@FierceBiotech: Boehringer pairs its lung cancer drug with a vaccine in $600M tie-up with CureVac. News | Follow @FierceBiotech
@JohnCFierce: Am I missing something? If the FDA eviscerates the low-T market, restricting use, doesn't that destroy the prospects of $RPRX, Clarus, etc.? | Follow @JohnCFierce
@DamianFierce: $NVO's eye on a Seattle expansion could be balm to local biotech as Amgen heads for the door. Article | Follow @DamianFierce
@EmilyMFierce: ICYMI: Check out these 7 notable academic-pharma alliances of 2014. Feature | Follow @EmilyMFierce
> Struggling Merck KGaA plans blockbuster R&D campaign for biosimilars, pact for PD-L1. Story
> Merck's weekly diabetes drug stacks up to blockbuster Januvia in Phase III. Report
> Oral low-T drugs in the pipeline face a showdown with the FDA. More
Pharma News
@FiercePharma: Now trending on FiercePharmaMarketing: First-to-market launch? Bonus--but double bonus if you're Big Pharma. Article | Follow @FiercePharma
@EricPFierce: Potentially bad news for Amphastar and its $155.7M deal if Sanofi makes insulin for Mannkind. More | Follow @EricPFierce
@CarlyHFierce: This week in FiercePharmaMarketing: Takeda lets 900 reps fly at obesity; AZ + James Van Der Beek = FluMist sales? More | Follow @CarlyHFierce
> Bayer brings $12.9B plastics spin-off to Big Pharma's slim-down party. Story
> Put a lid on 'Low-T' drug use, FDA panel advises, threatening AbbVie, Lilly meds. Article
> Real-world hep C patients drop off pricey Sovaldi, CVS study finds. More
Vaccines News
> Takeda reorg preps vaccines unit for emerging markets test. News
> 10 volunteers receive Glaxo Ebola vaccine with no adverse effects yet. Story
> Merck KGaA calls it quits on cancer vaccine--again. More
> Protein Sciences nabs stake in diabetes vax developer Diamyd. Story
> AstraZeneca sends James Van Der Beek 'camping' to promote FluMist Quadrivalent. Article
Pharma Manufacturing News
> More FDA issues arise for Hospira in India. News
> Novartis says more cuts coming for New York Diovan plant. More
> FDA procedural delay on Rytary gives Impax breathing room. Report
> Baxter issues recall, this time because antibacterial gets mixed in wrong carton. Story
> Partner Sanofi wants to produce the insulin to be used in MannKind's Afrezza. Article